Second Spinal Cord Injury Patient in Stem Cell Trial

Geron Corp’s Phase I trial is progressing with its second spinal cord injury patient receiving the company’s experimental embryonic stem cell therapy. The trial appears to be on track as serious side effects have not been reported for the first patient treated six months ago. While the primary objective is to establish the therapy’s safety profile in patients, like Neuralstem’s ALS trial, Geron’s trial will also look for potential early signs of clinical benefit.

Click here to read more.

Share this: